Interaction of central and peripheral benzodiazepine sites in benzodiazepine tolerance and discontinuation
| Autor: | Jonathan M. Koff, Lawrence G. Miller |
|---|---|
| Rok vydání: | 1994 |
| Předmět: |
Agonist
medicine.medical_specialty PK-11195 medicine.drug_class Pharmacology Benzodiazepines Mice chemistry.chemical_compound Drug tolerance Internal medicine Peripheral Nervous System mental disorders medicine Animals Humans Biological Psychiatry Benzodiazepine business.industry Antagonist Brain Lorazepam Drug Tolerance Receptors GABA-A Substance Withdrawal Syndrome Discontinuation Endocrinology Mechanism of action chemistry medicine.symptom business medicine.drug |
| Zdroj: | Progress in Neuro-Psychopharmacology and Biological Psychiatry. 18:847-857 |
| ISSN: | 0278-5846 |
| DOI: | 10.1016/0278-5846(94)90101-5 |
| Popis: | 1. Chronic administration of benzodiazepines is associated with the development of tolerance and discontinuation effects in humans and in a mouse model. 2. Co-administration of compounds active at the "peripheral" benzodiazepine site may alter chronic benzodiazepine effects. 3. During chronic lorazepam administration, addition of the peripheral site antagonist PK11195 attenuates behavioral tolerance and receptor downregulation. 4. In mice treated with both lorazepam and PK11195, discontinuation effects were also attenuated compared to lorazepam alone. 5. Specificity of the action of PK11195 was confirmed by antagonism of its action by the peripheral-site agonist Ro5-4864. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|